Clinical Trial Update: Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Vabomere to best available therapy in adults with serious infections; completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abdominal Infection
• Bacteremia
• Hospital-acquired Bacterial Pneumonia
• Pyelonephritis
• Urinary Tract Infection
• Ventilator-associated Bacterial Pneumonia

Drugs mentioned

• Best Available Therapy
• VABOMERE (MEROPENEM-VABORBACTAM)

Snippet

Sponsor: Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) | Conditions: Urinary Tract Infection Complicated, Acute Pyelonephritis | Phase 3 | Status: COMPLETED | Results posted: 2018-12-11